(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 March 2007 (08.03.2007)

PCT

(10) International Publication Number
WO 2007/026024 A3

(51) International Patent Classification:
A61K 31/5513 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:
PCT/EP2006/065938

(22) International Filing Date:
1 September 2006 (01.09.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05108058.8 2 September 2005 (02.09.2005) EP
05110606.0 10 November 2005 (10.11.2005) EP

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Eastgate Village,, Eastgate,, Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BONFANTI, Jean-François** [FR/FR]; 11 Impasse des Lauriers, F-27430 Andé (FR). **DOUBLET, Frédéric, Marc, Maurice** [FR/FR]; 1646, Route de Neufchatel, F-76230 Isneauville (FR). **NYANGUILE, Origène** [CH/BE]; Avenue du Grand Forestier 26A, B-1160 Brussels (BE). **RABOISSON, Pierre, Jean-Marie, Bernard** [FR/BE]; Rue Jolie 3, B-1331 Rosieres (BE). **REBSTOCK, Anne-Sophie, Helene, Marie** [FR/FR]; 54 Rue de Dudelange, F-57330 Volmerange-les-mines (FR). **BOUTTON, Carlo, Willy, Maurice** [BE/BE]; Rijksweg 115, B-8710 Wielsbeke (BE).

(74) Agent: **DAELEMANS, Frank**; Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
26 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BENZODIAZEPINES AS HCV INHIBITORS

(57) Abstract: The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates Io benzodiazepine compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

WO 2007/026024 A3